Short answer
A pre-ayahuasca medical screening is the collection and professional evaluation of current information about physical and mental health, medications, supplements, previous reactions, and recent changes in condition. It must occur before payment or final admission, include a clarifying conversation, and lead to a specific, transparent, and reasoned decision: acceptance, further consultation, postponement or a decision not to accept the application. Before arrival, the information must be updated again if there is a change in health, treatment or other important circumstances. Previous acceptance should then be reassessed in light of the new information.
A questionnaire is only one part of screening. Someone must review the answers, identify gaps or uncertainties and ask follow-up questions. If the answers automatically end with the message "you are accepted", the verification may be formal.
Screening does not prove that participation will be safe, and does not relieve the team of responsibility. Its purpose is to identify known factors, clarify the boundaries of competence, and prevent critical information from emerging for the first time during the ceremony.
Why is screening needed?
Ayahuasca components have psychoactive and pharmacological effects, including inhibition of monoamine oxidase A. Because of this, concomitant medications, cardiovascular conditions, seizure susceptibility, psychiatric history, and other factors are important. Pre-assessment helps identify known risks before a person is in a remote location.
Screening is also needed for planning. The team can find out if you need language support, accessible transport, special living arrangements or contact with a specialist. Important information does not always lead to an application being declined, but should influence the decision and readiness of the team.
Finally, the process shows the quality of communication. Can the participant honestly talk about the diagnosis without shame? Does the organizer explain why he asks the question? Do they avoid claiming that spiritual practice will neutralize medical risks?
What information is usually collected
The form should be specific enough, but not collect data without explanation. Usually relevant:
- diagnoses, operations, allergies and recent acute illnesses;
- cardiovascular, neurological and endocrine conditions;
- psychiatric history, episodes of psychosis, mania, severe depression or suicidal crisis;
- all prescription and over-the-counter drugs, supplements and other substances;
- pregnancy, breastfeeding and other relevant physiological circumstances;
- previous experience and adverse reactions to psychoactive substances.
This is not a ready-made medical protocol and is not a complete list for every situation. Its content should be determined by a competent specialist, taking into account the format. It is important to react to the answers: for example, clarify the unknown name of the drug or ask for an assessment of a specialized doctor.
How to list medications and supplements
Write down the name from the packaging or prescription, the active substance, the regularity of administration and the reason for use. Don't limit yourself to the category of "antidepressant," "sedative," or "something natural." A herbal supplement can also have a pharmacological effect.
Do not leave out a medication for fear that you will not be admitted. A decision made without complete data is not meaningful. Also, don't accept an individual medication withdrawal plan from the organizer unless they are a professional who can evaluate your therapy. An abrupt change in treatment may present a separate hazard.
If the drug was changed after the initial questionnaire, report it again. Our article on drug interactions explains why universal compatibility charts are misleading. The article on antidepressants examines that group of medications in more detail.
Assessment of mental status
Not only past diagnosis is important, but also current stability: sleep, anxiety, mood, orientation, recent crises, and support. A strong desire to urgently "solve everything" during an acute deterioration can be a reason not to speed up participation, but to seek specialized help.
A history of psychosis or mania, family predisposition, and previous severe reactions require special consideration. Simply asking "are there mental illnesses" is not enough: people may not know the terms, fear the stigma, or not consider the past episode to be important.
Screening should not become therapy. Its purpose is to assess whether the programme is suitable and the need for additional consultation. An acute crisis requires appropriate help, not persuasion that an intense experience is bound to be a turning point.
Who should evaluate the answers?
One person is not necessarily competent in all matters. The organizer may conduct the initial collection, the physician may assess physical conditions and medications, and the mental health professional may take the relevant history. It is important that the roles are named and that there is a way to refer questions to the appropriate professional.
Ask about the education, experience, and actual availability of the person doing the evaluation. The term "medical team" may refer to a full-time professional on site or a consultant who occasionally reviews individual cases. These arrangements offer different levels of access to care.

If a question is beyond the team’s expertise, they should explain what you need to discuss with your doctor. At the same time, the retreat's final decision on admission remains organizational: an external expert can assess the situation, but does not know all the conditions of a specific program.
What are the possible screening outcomes?
Screening should not be a system that always leads to a yes. Admission without additional conditions, request for clarification, professional consultation, postponement until the condition is stabilized or refusal are possible. The ability to say no is a sign that the process is meaningful.
Postponement is not a punishment and does not prove that a person is "insufficiently prepared spiritually." This is a decision under specific circumstances that may change. The organizer should explain what information is needed for re-evaluation, without prescribing changes to treatment outside their expertise.
If the admission depends on the consultation, specify who will consider its conclusion and whether the questionnaire needs to be filled out again. Do not buy tickets until important details are finalized if the trip depends on the outcome.
Privacy and information updates
The organizer must explain who sees the questionnaire, where it is stored, for how long and to whom it is given. The residential coordinator does not necessarily need to know the entire medical history, while the duty team may need brief practical information to respond.
A participant must understand this distribution before sending sensitive data. At the same time, confidentiality does not mean that information can be withheld from the people responsible for the assessment. Access should be limited to what each person needs for their role.
The team must ask about changes before arrival. An infection, injury, new prescription, acute insomnia, or crisis episode can render an old assessment irrelevant. The preparation article contains a more extensive checklist.
Limits of screening
Even a thorough process works with incomplete information. A person may not be aware of the condition, the drug may have a different trade name, and the reaction may remain individual. Acceptance means only that, based on the available data, the team found no reason for a different decision.
Screening is not a substitute for the right environment, sober helpers, and a response plan. Likewise, it does not justify the lack of assistance with the phrase "the participant signed everything himself." Screening before participation and monitoring during the programme are separate responsibilities.
When comparing centers, look not at the length of the questionnaire, but at the dialogue and decision. The article on choosing a retreat discusses these criteria alongside the team, venue and support.
Evidence base and uncertainty
Pharmacological reviews describe the activity of DMT and beta-carbolines and the potential for interactions. Clinical studies often use careful selection, controlled environments, and observations, so their results cannot be automatically transferred to any retreat.
User surveys record unwanted physical and psychological effects, but self-reports do not determine exact individual risk. There is no single validated questionnaire that guarantees results in all formats. Screening must combine available data with professional judgment and honest recognition of boundaries.
Signs of superficial screening
The problematic process often looks convincing on the surface: a long questionnaire, many mandatory fields and an automated email. However, no one clarifies the conflicting answers, names the person evaluating the data, or explains the possible results. The size of the form does not compensate for the lack of professional judgment.
Another sign is the search for the "correct" answer. The coordinator can suggest how to reformulate the condition so that the system accepts the application, or dismiss a diagnosis as mere fear or a lack of trust. Such behavior changes the purpose of screening: instead of identifying risk, it becomes an obstacle to be circumvented together.
One warning sign is a blanket recommendation to take a break from any drug, regardless of the active substance and the history of the person. A competent response recognizes that different agents have different mechanisms and that discontinuation may require observation. The organizer should direct the question to the relevant specialist, and not issue one template to everyone.
Screening also becomes a formality if it is completed before payment but never updated before participation. Weeks can pass between the questionnaire and the trip: sleep, mood, treatment and physical condition change during this time. A brief reconfirmation and an available channel to communicate changes should be part of the process.
Finally, screening loses its meaning if the team is not ready to act on its findings. Information about a previous severe reaction should influence the decision, the allocation of attention, or the request for additional evaluation. If every answer leads to automatic acceptance, the participant cannot rely on the mere fact of filling out the form.
A participant can assess the quality of the process by simply asking: "What exactly will happen to my questionnaire after submission?" A good answer names the person or role, the review period, the method of clarification, possible outcomes, and the procedure for updating the data. If the answer is limited to a phrase about confidentiality or spiritual preparedness, ask for an explanation of the operational steps. Screening should be a transparent process, not an unexplained decision behind closed doors.